Bromide

Bromide

SCHEMBL5164587

Br.Br.NCCCCCC1(N)CCC1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A known ✓ Q12879 1/20 0.35
SIGMAR1 known ✓ Q99720 1/20 0.32
DNM1 Q05193 5/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA3 P07451 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
BLM P54132 1/20 0.38
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7862753 0.98 DNM1 (0.40) DNM1CA12CA1CA2CA3
SCHEMBL6868041 0.93 CA12 (0.40) DNM1CA12CA1CA2CA3
SCHEMBL16416350 0.91 CPB2 (0.41) DNM1CA12CA1CA2CA3
SCHEMBL11967584 0.91 CPB2 (0.41) DNM1CA12CA1CA2CA3
SCHEMBL27975115 0.90 GRIN2D (0.38) DNM1CA12CA1CA2CA3
SCHEMBL24838601 0.85
SCHEMBL9551519 0.82 GRIN2D (0.36) DNM1CA12CA1CA2CA3
SCHEMBL3193842 0.80 GRIN2D (0.34) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30895346 0.76 GRIN2D (0.39) DNM1CA12CA1CA2CA3
SCHEMBL8416075 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0820338-B1 WHOLE BLOOD SEPARATION METHOD AND DEVICES LIFESCAN INC (US) 2007-03-14 EP disclosed
EP-1361436-B1 Multilayer reagent test strips and methods for using the same to quantify glycated protein in a physiological sample LIFESCAN INC (US) 2006-11-15 EP disclosed
US-20050255453-A1 Multilayer reagent test strips and methods for using the same to quantify glycated protein in a physiological sample LIFESCAN, INC. 2005-11-17 US disclosed
US-6951728-B2 Multilayer reagent test strips to quantify glycated protein in a physiological sample LIFESCAN, INC. (US) 2005-10-04 US disclosed
US-20030211564-A1 Multilayer reagent test strips and methods for using the same to quantify glycated protein in a physiological sample LIFESCAN IP HOLDINGS, LLC 2003-11-13 US disclosed
EP-1361436-A1 Multilayer reagent test strips and methods for using the same to quantify glycated protein in a physiological sample Lifescan, Inc. (US) 2003-11-12 EP disclosed
EP-0820338-A4 WHOLE BLOOD SEPARATION METHOD AND DEVICES LXN CORP (US) 1998-12-09 EP disclosed
US-5762871-A ANALYZING FRUCTOSAMINE OR GLUCOSE IN BLOOD SAMPLE LXN CORP. (US) 1998-06-09 US disclosed
US-5725774-A PERMEABLE MATRIX CONTAINING POLYOL THAT CLUMPS ERYTHROCYTES; TEST FOR GLUCOSE OR FRUCTOSAMINE LXN CORP. (US) 1998-03-10 US disclosed
EP-0820338-A1 WHOLE BLOOD SEPARATION METHOD AND DEVICES LXN Corporation (US) 1998-01-28 EP disclosed
WO-1996031270-A1 WHOLE BLOOD SEPARATION METHOD AND DEVICES LXN CORPORATION (US) 1996-10-10 WO disclosed